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1he role of cardioprotection in breast cancer 
The evolution of breast cancer treatment, both with advances
n detection and treatment, has led to a signiﬁcant increase in sur-
ival rates. Although approximately 268,600 new cases of female
reast cancer are projected to occur in 2019 with 41,760 estimated
eaths [1] , the overall 5-year survival rate at all stages remains
igh at 89.7% for all cases, and 98.7% for localized female breast
ancer [2] . There were an estimated 3.56 million breast cancer sur-
ivors living in the United States as of 2016, which is projected to
ncrease to 4.57 million in 2026 [3] . 
As a result, with many cases either deemed curable or control-
able under maintenance therapy, the focus inevitably turns to the
ttention of the short- and long-term cardiovascular health of the
reast cancer patient. Cardiovascular disease remains the top over-
ll cause of death in adult females, and it is likely that this will
ffect many of those who survive breast cancer. In a minority of
atients, cardiotoxic effects of cancer treatment will potentiate the
isk for cardiac events — whether it be exposure to anthracyclines
nd/or anti-HER2 agents such as trastuzumab, with the possible
ddition of radiation therapy, whose older techniques are linked
o long-term cardiac events. Despite the emergence of the multi-
isciplinary ﬁeld of cardio-oncology with international effort s to
lucidate the mechanisms and devising strategies to prevent car-
iotoxiciy through randomized controlled trials, it still largely re-
ains a mystery as to which patients are at risk for cardiotoxicity,
nd which patients beneﬁt most from cardioprotective strategies. ∗ Corresponding author at: University of Washington Medical Center, Box 356422, 
eattle, WA 98195, United States. 
E-mail address: rkcheng@uw.edu (R.K. Cheng). 
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050-1738/© 2019 Elsevier Inc. All rights reserved. In a systematic fashion, Padegimas and colleagues perform a
tate-of-the-art review [4] of cardioprotective trials with results
hus far that have overall shown only limited eﬃcacy. Most of
hese cardioprotection trials have borrowed treatment strategies
rom other subspecialities in cardiology, particularly heart failure
HF). However, the data regarding neurohormonal blockade from a
ardioprotective approach is not well-established compared to the
umerous studies conﬁrming eﬃcacy in patients with existent left
entricular dysfunction (LVD). Regardless, beta-blockers (BB) and
ngiotensin converting enzyme inhibitors (ACEi) have most often
een tested. 
These pharmacologic medications have proven their beneﬁt in
ther cardiomyopathy cohorts and shown some cardioprotective
ole in smaller institutional studies. However, in these larger-scale
rials being discussed, many of which have been conducted on a
ulti-institutional scale, results are at odds with earlier observa-
ional studies. For instance, Cardinale and colleagues previously
emonstrated that in patients with anthracycline induced car-
iomyopathy, early detection and introduction of cardioprotection
an increase the likelihood of ejection fraction (EF) recovery and
educe cumulative cardiac events [5] . She followed this study with
 prospective evaluation of a heterogenous cohort of patients re-
eiving anthracyclines. Of the breast cancer patients in this group,
.7% experienced cardiotoxicity, with 98% of cardiotoxicity occur-
ing within the ﬁrst year after treatment, with 11% achieving full
nd 71% showing partial recovery of EF with aggressive medical
herapy [7] . In other disease states, carvedilol and enalapril re-
uced the incidence of LVD in a randomized cohort of patients un-
ergoing hematopoietic stem cell transplantation [6] . These limited
tudies suggest that in an older patient cohort with cardiovascular
isease and/or risk factors, and with higher doses of chemotherapy
nd radiation therapy, cardiotoxicity is more frequently seen. 
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Fig. 1. Finding the “sweet spot” (middle ground) of patients who will beneﬁt from cardioprotective strategies for cancer treatment. 
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c  Thus, along the entire spectrum of breast cancer patients, there
remains a challenging-to-identify subcohort of patients who can
potentially beneﬁt from cardioprotective therapy, with most pa-
tients on one end of the spectrum who experience no signiﬁ-
cant consequences from cancer treatments ( Fig. 1 ). On the other
end, there is a minority of patients who experience cardiotoxic-
ity, which have variable response to treatment, of which many do
not completely recover and with unclear long term cardiovascular
prognostic implications. Our knowledge remains nascent compared
to the wealth of data that has arisen from vast, large-scale trials
performed in other cardiovascular diseases. 
What the trials have taught us so far 
To address the discordance in results, it is imperative to con-
sider several fundamental features of cardioprotection studies. One
crucial element is the baseline risk for developing cardiovascular
events. Taking a young, low risk cohort would yield very different
results than an older, higher risk cohort due to drastically diverging
event-rates and residual cardiac reserve for additional exposure.
Higher risk patients are not only more likely to develop cardiac
events from initial exposure, but also more likely to suffer events
with additive, incremental insults. In large cardioprotection trials
to date, cohorts have been predominantly low-to-intermediate risk,
excluding most high-risk patients. 
Another factor is the degree of treatment risk; it is known
that with certain cancer treatments such as anthracyclines and
radiation therapy, risk is related to increasing doses of exposure,
while other therapies such as trastuzumab are not dose-dependent.
Newer agents including the tyrosine kinase inhibitors and im-
munotherapy require additional evaluation for speciﬁc thresholds
and timing of risk. We lack data on high-risk cohorts being ex-
posed to high-risk treatment, even though these are the patients
that stand to beneﬁt most from an effectively im plemented car-
dioprotection strategy. 
Thirdly, the intensity and timing of intervention must be con-
sidered. Are patients being given monotherapy (ACEi or BB alone)
or dual therapy (ACEi and BB), how aggressively are patients up-
titrated on these medications, and what proportion of patients
meet target dosing? Dose titration can be challenging in an oth-
erwise healthy cohort without pre-existing hypertension and inany cases, target doses used in HF trials will not be achieved. For
ost therapies, we do not know the effective dose for a cardiopro-
ection strategy, which may not necessarily align with threshold
osing for treating HF. 
Timing of intervention may also be essential, as it is unclear
hether cardioprotection should be instituted prior to treatment,
uring treatment, or only when there is evidence of injury. The
ecent ICOS-one (International CardioOncology Society) trial found
hat a preventative treatment strategy was not more effective than
ne targeting patients after injury. These results suggest that use of
CEi might only be effective in those that suffer injury, rather than
n a primary prevention approach [7] . This could explain why ob-
ervational studies have shown beneﬁt of neurohormonal blockade
n cases of cardiotoxicity that has not been consistently reproduced
n clinical trials that start therapies prior to treatment. 
For any ideal clinical trial, judicious selection of the outcome
easure is critical. It remains unclear whether commonly used
urrogate endpoints in cardio-oncology trials including reduction
n EF, reduction in strain, or elevation in biomarkers translates to
ard clinical events of clinical heart failure or short/long term car-
iovascular mortality. Confounding endpoints such as cancer re-
ated comorbidity and mortality can also pose unique challenges
n cardio-oncology. 
Also problematic is that within the conﬁnes of a speciﬁc out-
ome, there may be variability in the deﬁnition of cardiotoxicity.
or example, LV function was measured differently in several land-
ark cardioprotection trials. In the PRADA (prevention of cardiac
ysfunction during adjuvant breast cancer therapy) study, LV func-
ion was estimated based on cardiac MRI, with a primary outcome
easure of change in LVEF from baseline of 5% as the threshold for
linical importance [8] . In MANTICORE-101 (multidisciplinary ap-
roach to novel therapies in cardio-oncology research), LV function
as measured with cardiac MRI with deﬁnition for cancer-related
ardiac dysfunction deﬁned as a drop in LVEF ≥ 10% to a value of
 53% [9] . More recently, the CECCY (carvedilol for prevention of
hemotherapy-related cardiotoxicity) study used echocardiography
ith a drop in LVEF of at least 10% from baseline until the end
f chemotherapy at 6 months as the endpoint [10] . Standardized
mage acquisition and deﬁnitions for cardiotoxicity would ensure
onsistency in the management of patients and permit accurate
omparisons between studies. Further, consistent use of core labs
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 hould be considered a priority in cardio-oncology trials to guar-
ntee the reproducibility and reliability of measurements in a ﬁeld
losely aligned with imaging. 
rojecting future directions of the ﬁeld 
Although the early cardioprotection trials have been truly land-
ark studies in an underexplored ﬁeld, current trials extend this
nowledge to higher risk treatment and have expanded the do-
ain of cardioprotection beyond pharmacologic intervention to
ther aspects of care, including biomarker and imaging guided
trategies. Although not discussed in the current review, there is
ounting interest in exercise as a cardioprotective strategy during
reast cancer treatment. 
Moving forward, there remain many unanswered questions.
e lack comprehensive studies targeting aggressive risk factor
eduction to determine if it would translate into meaningful
eneﬁt during cancer treatment. There is robust literature from
hildhood survivors on the effectiveness of treating comorbidities
hat is lacking in the adult population [11] . A “one size ﬁts all”
trategy may not be the best approach for cardioprotection. In an
ra of personalized medicine and targeted strategies in oncology,
e need to consider a similar approach in cardio-oncology, as not
ll patients are of equivalent risk or similar exposure. 
Improved insights into the mechanisms for cardiotoxicity may
dentify novel therapeutic targets. The hope is not for newer in-
erventions to displace ones currently being tested, but to uncover
nes with incremental and synergistic beneﬁt. The National Cancer
nstitute (NCI) has shifted their focus from the use of biomarkers,
tandardizing imaging, and prevention with established cardiac
edications to more mechanistic evidence-based models, risk
tratiﬁcation, and modiﬁable risk factors [12] , aligning with many
esearchers seeking to expand cardioprotection strategies into
ncharted realms. 
Recent studies have highlighted the interaction of biological
athways on cancer and cardiovascular outcomes. For example, in-
ammation is a common mechanism for atherosclerosis and cancer
isk. In the CANTOS trial (Canakinumab Anti-Inﬂammatory Throm-
osis Outcomes Study), use of a human monoclonal antibody tar-
eting interleukin 1 β conferred both cardiovascular beneﬁt and a
ecrease in lung cancer incidence [13] . Whether similar pathways
inking cancer and LV dysfunction requires further exploration but
eads to the intriguing concept of whether underexplored path-
ays may play key roles in both disease states and serve as po-
ential targets. 
In summary, future studies would beneﬁt from rigorous se-
ection for baseline risk, preexisting cardiovascular risk factors,reatment exposure, intensity of intervention, and endpoints.
xpanding beyond our current repertoire of pharmacologic options
s needed, including better understanding of how aggressively we
hould treat comorbidities, and discovery of new therapeutic tar-
ets in this unique population. Clearly, there are more unknowns
han knowns in this ﬁeld. These are exciting times in cardio-
ncology as there are many ongoing and upcoming trials designed
o address some of these gaps as Padegimas and colleagues high-
ighted, and we move toward an era of effective cardioprotection
n a coordinated effort with our oncology colleagues to ﬁnd the
sweet spot” of patients who will beneﬁt. 
eferences 
[1] Siegel RL , Miller KD , Jemal A . Cancer statistics, 2019. CA Cancer J Clin
2019;69:7–34 . 
[2] Cancer Stat Facts: Female Breast Cancer. From: https://seer.cancer.gov/statfacts/ 
html/breast.html . Accessed 30 January 2019. 
[3] Miller KD , Siegel RL , Lin CC , Mariotto AB , Kramer JL , Rowland JH , et al. Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271–89 . 
[4] Padegimas A , Clasen S , Ky B . Cardioprotective strategies to prevent breast can-
cer therapy-induced cardiotoxicity. Trends Cardiovasc Med 2019 . 
[5] Cardinale D , Colombo A , Lamantia G , Colombo N , Civelli M , De Giacomi G ,
et al. Anthracycline-induced cardiomyopathy: clinical relevance and response
to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–20 . 
[6] Bosch X , Rovira M , Sitges M , Domenech A , Ortiz-Perez JT , de Caralt TM ,
et al. Enalapril and carvedilol for preventing chemotherapy-induced left ven-
tricular systolic dysfunction in patients with malignant hemopathies: the
OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and
caRvedilol in patients submitted to intensive ChemOtherapy for the treatment
of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355–62 . 
[7] Cardinale D , Ciceri F , Latini R , Franzosi MG , Sandri MT , Civelli M , et al. Anthra-
cycline-induced cardiotoxicity: a multicenter randomised trial comparing two
strategies for guiding prevention with enalapril: the International CardioOncol-
ogy Society-one trial. Eur J Cancer 2018;94:126–37 . 
[8] Gulati G , Heck SL , Ree AH , Hoffmann P , Schulz-Menger J , Fagerland MW ,
et al. Prevention of cardiac dysfunction during adjuvant breast cancer ther-
apy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind
clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671–80 . 
[9] Pituskin E , Mackey JR , Koshman S , Jassal D , Pitz M , Haykowsky MJ , et al. Mul-
tidisciplinary approach to novel therapies in cardio-oncology research (MAN-
TICORE 101-breast): a randomized trial for the prevention of trastuzumab-as-
sociated cardiotoxicity. J Clin Oncol 2017;35:870–7 . 
10] Avila MS , Ayub-Ferreira SM , de Barros Wanderley MR Jr , das Dores Cruz F ,
Goncalves Brandao SM , Rigaud VOC , et al. Carvedilol for prevention of
chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol
2018;71:2281–90 . 
[11] Armstrong GT , Oeﬃnger KC , Chen Y , Kawashima T , Yasui Y , Leisenring W ,
et al. Modiﬁable risk factors and major cardiac events among adult survivors
of childhood cancer. J Clin Oncol 2013;31:3673–80 . 
12] Shelburne N , Simonds NI , Adhikari B , Alley M , Desvigne-Nickens P , Dimond E ,
et al. Changing hearts and minds: improving outcomes in cancer treatment-re-
lated cardiotoxicity. Curr Oncol Rep 2019;21:9 . 
13] Ridker PM , Everett BM , Thuren T , MacFadyen JG , Chang WH , Ballantyne C ,
et al. Antiinﬂammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med 2017;377:1119–31 . 
